Predictive Technology Group Inc (PRED)

[High_Profits]

PRED Shares Are Valuable. To support valuation, in part, consider:

Dr. Taylor's published research papers and data to be presented at ASRM, and the launch of PRED's ARTguide genetic diagnostics for endometriosis and the 24 million U.S. women who are symptomatic (and 14 million diagnosed) with endometriosis;

PRED's Mike Day who was the key executive that built Wyeth Women's Health, e.g., Wyeth was sold to Pfizer in 2009 for $68 billion;

John Sorrentino, PRED's Chairman who was until early this year COO and SVP at Pfizer responsible for $34+ billion in annual revenue;

And other seasoned individuals within PRED of equal track records in life science and public companies.

2019 ASRM and PRED's ARTguide:
ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in-vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

Three scientific presentations by PRED's Dr. Hugh Taylor highlighting recent discoveries by Predictive Laboratories were selected through ASRM’s scientific peer-review process. The presentations will focus on several features of endometriosis, including genetic mechanisms (ARTguide) underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous. The content of these presentations is embargoed until data are presented at the conference. Patent applications have been filed around these new discoveries adding to the Company’s robust endometriosis patent portfolio.
https://asrm.confex.com/asrm/2019/meetingapp.cgi/Person/739

The ARTguide Market and Revenue:
The market revenue from ARTguide is rather simple (remember there are 24 million endometriosis symptomatic undiagnosed women in the U.S.;

Survey data indicates all fertility clinics are interested in ARTguide;
A significant percentage (35 to 40%) of those clinics will order the ARTguide test for new patients;
And new and existing female patients equal an average of 35 prescriptions per month per doctor.
Initially, 15 larger clinics for clinical research are interested, and;
Assume 12 (of the 15 clinics), each with 9 doctors will produce $150 million in annual revenue from the ARTguide diagnostic;
Now consider 200 infertility doctors in the U.S. prescribing 35 prescriptions per month, which produces over $3.3 billion in annual revenue.
There are 480+ female reproduction and fertility doctors identified (highly confident) that will use ARTguide in the U.S.

The Big Picture Challange of Connecting the BIG FLASHING DOTS:
The 2019 American Society for Reproductive Medicine (ASRM) will be attended by 9,300 reproductive doctors, specialists, and scientists, from 94 countries, representing a diagnosed endometriosis population of 176 million, and an estimated undiagnosed population of another 128 million women (for those that have been paying attention, China has 74+ million women diagnosed with endometriosis).
https://asrmcongress.org/

Consider PRED's U.S. and internationally patented ARTguide diagnostic is being launched on the market at the world's leading reproductive conference (ASRM) attended by over 9,300 reproductive specialists, representing a global diagnosed and undiagnosed endometriosis population of 300+ million women.
https://www.rightdiagnosis.com/e/endometriosis/stats-country.htm

PRED's Near Term Market Cap?
Use the below PE, and note there are many other companion proprietary gene diagnostics and therapeutics in PRED's pipeline but let's just consider the multiples for ARTguide.